Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Mylan NV Ord Shs (MYL)

Mylan NV Ord Shs (MYL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,586,212
  • Shares Outstanding, K 541,546
  • Annual Sales, $ 11,501 M
  • Annual Income, $ 16,800 K
  • 60-Month Beta 1.45
  • Price/Sales 0.73
  • Price/Cash Flow 1.90
  • Price/Book 0.68
Trade MYL with:
  • Price/Earnings ttm 3.29
  • Earnings Per Share ttm 4.73
  • Most Recent Earnings $0.36 on 11/06/20
  • Latest Earnings Date N/A
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend 0.060 on 06/27/07
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate 1.35
  • Number of Estimates 6
  • High Estimate 1.50
  • Low Estimate 1.25
  • Prior Year 1.40
  • Growth Rate Est. (year over year) -3.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
14.00 +13.24%
on 10/29/20
16.15 -1.83%
on 11/16/20
+0.14 (+0.92%)
since 10/16/20
3-Month
14.00 +13.24%
on 10/29/20
17.03 -6.90%
on 08/19/20
-0.34 (-2.07%)
since 08/14/20
52-Week
12.75 +24.35%
on 03/16/20
23.11 -31.39%
on 02/06/20
-1.85 (-10.42%)
since 11/15/19

Most Recent Stories

More News
WWE® Elects Michelle McKenna & JoEllen Lyons Dillon to Board of Directors

WWE ® (NYSE: WWE) today announced that Michelle McKenna and JoEllen Lyons Dillon have been elected to its Board of Directors.

RNG : 34.74 (-0.40%)
NSP : 109.61 (+0.96%)
VRTS : 247.98 (+0.15%)
MYL : 15.86 (+1.96%)
DM : 0.8800 (+1.15%)
WWE : 100.65 (+2.65%)
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Viatris Inc. and Encourages Investors who Formerly Held Shares of Mylan Inc. (MYL) to Contact the Firm

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Viatris Inc. (“Viatris” or “the Company”) (NASDAQ: VTRS...

MYL : 15.86 (+1.96%)
VTRS : 11.94 (+0.93%)
FDA allows automatic 'generic' swap for brand-name insulin

U.S. regulators took action Wednesday that will make it easier to get a cheaper, near-copy of a brand-name insulin at the drugstore.

MYL : 15.86 (+1.96%)
Mylan and Pfizer Receive Clearance from the U.S. Federal Trade Commission for Proposed Combination of Mylan and Upjohn

Mylan N.V. (NASDAQ: MYL) and Pfizer Inc. (NYSE: PFE) today announced that the U.S. Federal Trade Commission (the “FTC”) accepted a proposed consent order, which concludes the FTC’s review of the...

MYL : 15.86 (+1.96%)
PFE : 27.75 (-0.11%)
Mapi Pharma Announces Commissioning of a Vaccine Production Facility to Support the Supply of COVID-19 Vaccines to Israel and EU Countries

Facility in the Jerusalem Har-Hotzim technology park is built at the highest GMP standards; capability to provide reliable supply of COVID-19 vaccines, if approved

MYL : 15.86 (+1.96%)
Mapi Pharma Presents Glatiramer Acetate Depot (GA Depot) Results at the 8th Joint ACTRIMS-ECTRIMS Meeting MSVirtual2020

90% of relapsing remitting multiple sclerosis (RRMS) patients on GA Depot demonstrated no evidence of disease activity (NEDA) at four years

MYL : 15.86 (+1.96%)
ROSEN, A LEADING LAW FIRM, Reminds Mylan N.V. Investors of Important Tuesday Deadline in Securities Class Action – MYL

NEW YORK, Aug. 23, 2020 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Mylan N.V. (NASDAQ: MYL) between February 16, 2016 and May 7, 2019,...

MYL : 15.86 (+1.96%)
ROSEN, A LONGSTANDING AND TRUSTED FIRM, Reminds Mylan N.V. Investors of Important Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm – MYL

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Mylan N.V. (NASDAQ: MYL) between February 16, 2016 and May 7, 2019, inclusive (the “Class Period”), of the...

MYL : 15.86 (+1.96%)
NetworkNewsBreaks – Eastman Kodak Co. (NASDAQ: KODK) Stock Heads Skyward after Company Receives First-of-Its-Kind Government Loan

Eastman Kodak Co.’s (NASDAQ: KODK) stock tripled following the announcement that the once-bankrupt company had received a $765 million loan from the Trump administration to fund a pharmaceutical ingredients...

KODK : 4.95 (+3.12%)
F : 13.28 (+1.68%)
GM : 45.35 (+1.70%)
AMRX : 6.06 (-0.98%)
MYL : 15.86 (+1.96%)
TEVA : 14.11 (-2.22%)
NVS : 96.73 (+0.89%)
PINC : 22.10 (+1.38%)
ROSEN, A LEADING, LONGSTANDING, AND TOP RANKED FIRM, Reminds Mylan N.V. Investors of Important Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm – MYL

NEW YORK, July 18, 2020 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Mylan N.V. (NASDAQ: MYL) between February 16, 2016 and May 7, 2019,...

MYL : 15.86 (+1.96%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Mylan, Inc. was incorporated in Pennsylvania in 1970. The Company and its subsidiaries comprise a global pharmaceutical company that develops, licenses, manufactures, markets and distributes generic and branded generic pharmaceuticals, specialty pharmaceuticals and active pharmaceutical ingredients ('API')....

See More

Key Turning Points

3rd Resistance Point N/A
2nd Resistance Point 16.59
1st Resistance Point 16.22
Last Price 15.86
1st Support Level 15.41
2nd Support Level 14.97
3rd Support Level N/A

See More

52-Week High 23.11
Fibonacci 61.8% 19.15
Fibonacci 50% 17.93
Fibonacci 38.2% 16.71
Last Price 15.86
52-Week Low 12.75

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar